Industry News

• Illumina reports financial results for fourth quarter and fiscal year 2011  Illumina reported revenue of $250 million, a 4% decrease compared to the $261 million in the fourth quarter of 2010. GAAP net income for the quarter of $11.7 million, or $0.09 per diluted share, compared to net income of $38.4 million, or $0.25 per diluted share, for the fourth quarter of 2010.
  February 07, 2012  
• Avanir Pharmaceuticals reports fiscal 2012 first quarter financial results  Avanir reported the net loss for the fiscal 2012 first quarter was $15.9 millionversus a net loss of $12.1 million for the same period in fiscal 2011. Net revenues for the quarter ended December 31, 2011 were $7.2 million versus $1.8 million for the comparable 2011 quarter.
  February 07, 2012  
• USANA Health Sciences announces fourth quarter and full-year 2011 financial results  USANA Health Sciences reported net sales in the fourth quarter of 2011 increased by 6.1% to $145.9 million, compared with $137.5 million in the prior year period. Net earnings in the fourth quarter increased by 6.2% to $13.2 million, compared with the prior year period.
  February 07, 2012  
• Life Technologies announces fourth quarter and fiscal year 2011 results  Life Technologies reported 2011 revenue increased 4 percent to $3.7 billion; GAAP EPS increased to $2.23, or $3.73 on a non-GAAP basis, an increase of 5 percent. 2011 free cash flow totaled $710 million.
  February 07, 2012  
• Ligand reports fourth quarter and full year 2011 financial results  Ligand reported net income for the fourth quarter of 2011 was $4.8 million versus net income for the fourth quarter of 2010 of $4.5 million. Total revenues for the fourth quarter of 2011 were $12.9 million versus $3.9 million for the fourth quarter of 2010.
  February 07, 2012  
• Illumina's board unanimously rejects Roches unsolicited tender offer as inadequate  Illumina announced that its Board of Directors reviewed Roche’s unsolicited tender offer with the assistance of its financial and legal advisors and unanimously determined that the $44.50 per share cash offer is grossly inadequate and is contrary to the best interests of Illumina’s stockholders.
  February 07, 2012  
• 3M increases dividend for the 54th consecutive year  The Board of Directors of 3M declared a dividend on the company’s common stock of 59 cents per share for the first quarter of 2012, a 7 percent increase over the quarterly dividend paid in 2011. The dividend is payable on March 12, 2012.
  February 07, 2012  
• Harvard Bioscience acquires AHN Biotechnologie  Harvard Bioscience announced that it has acquired the business of AHN Biotechnologie GmbH through its wholly owned Biochrom Ltd. subsidiary. AHN is a privately held manufacturer of plastic consumable laboratory products including pipette tips.
  February 07, 2012  
• Vyvanse® capsules now approved in the US for maintenance treatment in adults with ADHD  Shire announced the FDA approved the prescription medication Vyvanse® (lisdexamfetamine dimesylate) Capsules, as a maintenance treatment for adults with ADHD. The approval is based on results from a randomized withdrawal study designed to evaluate the efficacy of Vyvanse.
  February 07, 2012  
• Administration announces new steps to fight Alzheimer’s disease  The Obama Administration announced new efforts to fight Alzheimer’s disease, including immediately making an additional $50 million available for cutting-edge research. In addition, the administration announced that its FY 2013 budget will boost funding for Alzheimer’s research by $80 million.
  February 07, 2012  

   (next 10 articles)